Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18237098 | 1.00 | KMT2A (0.53) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29514568 | 1.00 | KMT2A (0.53) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL26093325 | 1.00 | KMT2A (0.53) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29875729 | 1.00 | KMT2A (0.53) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL15521165 | 1.00 | KMT2A (0.53) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL120403 | 1.00 | KMT2A (0.53) | KMT2AMDM2MDM4TP53TLR2 | |
| Hydrochloric Acid SCHEMBL9661481 | 0.99 | KMT2A (0.52) | KMT2AMDM2MDM4TP53TLR2 | |
| Hydrochloric Acid SCHEMBL29365362 | 0.99 | KMT2A (0.52) | KMT2AMDM2MDM4TP53TLR2 | |
| Hydrochloric Acid SCHEMBL29400592 | 0.99 | KMT2A (0.52) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29432853 | 0.97 | KMT2A (0.54) | KMT2AMDM2MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118620027-A | Preparation method of icatibant | 武汉武药科技有限公司 | 2024-09-10 | — | — | CN | claimed |
| CN-116947966-B | Method for preparing itracin intermediate and itracin | 哈药集团生物工程有限公司 | 2023-12-26 | — | — | CN | claimed |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| CN-121914210-A | Method for preparing ETELCALCETIDE by combining solid and liquid | 浙江工业大学 | 2026-04-24 | — | — | CN | disclosed |
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-31 | — | — | US | disclosed |
| EP-3727461-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-4582436-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BicycleTX Limited (GB) | 2025-07-09 | — | — | EP | disclosed |
| CN-118754946-A | Cationic polypeptide with tumor targeted permeation effect and preparation method and application of micelle of cationic polypeptide | 上海交通大学医学院附属第九人民医院 | 2024-10-11 | — | — | CN | disclosed |
| CN-118620027-A | Preparation method of icatibant | 武汉武药科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-118620027-A | Preparation method of icatibant | 武汉武药科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-4069684-A2 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | ETH Zurich (CH) | 2022-10-12 | — | — | EP | disclosed |
| US-20220289792-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LIMITED (GB) | 2022-09-15 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-114773433-B | CD25 targeted polypeptide, molecular probe and application | 北京肿瘤医院(北京大学肿瘤医院) | 2022-09-06 | — | — | CN | disclosed |
| US-20220218852-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-07-14 | — | — | US | disclosed |
| WO-2022149612-A1 | METHOD FOR PRODUCING PEPTIDE | 日産化学株式会社 | 2022-07-14 | — | — | WO | disclosed |
| CN-114364690-A | Novel radiolabeled CXCR4 targeting compounds for diagnosis and therapy | 省卫生服务机构 | 2022-04-15 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| EP-3956346-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | Provincial Health Services Authority (CA) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | CXCR4, CXCL12, ACKR3 | KMT2A 4385/4885MDM2 4231/4885MDM4 4337/4885 |
| US-20220218852-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | CXCR4, CXCR1, FPR1 | KMT2A 3303/4885MDM2 3813/4885MDM4 4011/4885 |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | EPHA2, EPHB2, ERBB2 | KMT2A 1304/4885MDM2 284/4885MDM4 4213/4885 |
| US-20220289792-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | EPHA2, EPHB2, ERBB2 | KMT2A 2073/4885MDM2 241/4885MDM4 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.